Yahoo Finance

Ampio's Independent Committee Launches Investigation Related To AP-013 Trial

Ampio Pharmaceuticals Inc's (NYSE: AMPE) independent special Committee of the Ampio Board of Directors has started an internal investigation regarding Ampio's AP-013 trial with the assistance of ...
Nasdaq

Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III ...
Nasdaq

Ampio Pharmaceuticals Announces Top-line Results from AP-013 Phase III Study of Ampion in Adult Patients Suffering from Severe Osteoarthritis of the Knee (OAK)

- Ampio's current cash runway of approximately 12 months expected to provide sufficient near-term liquidity and flexibility to support existing business operations - Ampio plans to meet with the Food ...
Yahoo Finance

Ampio Highlights Promising Ampion Data In Knee Osteoarthritis

Ampio Pharmaceuticals Inc (NYSE: AMPE) announced data from the modified Intent-to-Treat (mITT) population in the AP-013 Phase 3 trial of Ampion in severe osteoarthritis of the knee (OAK). The AP-013 ...